Pfizer acquires commercial rights to Biohaven migraine drug outside the US
![Photo: Dado Ruvic/REUTERS / X02714](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13455393.ece/ALTERNATES/schema-16_9/doc7id2e9fswrrr2l1maz8.jpg)
Pfizer has acquired the commercial rights of the US-based biotech company Biohaven's migraine drug Nurtec outside of the US, it reports in a press release.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
FDA approves Abbvie's preventative migraine tablet
For subscribers
Sales of Biohaven's migraine tablet exceed expectations
For subscribers
FDA approves migraine pill as preventative treatment
For subscribers